Optimizing Biosimilar Implementation: A Framework for Access, Adoption, and Sustainability
Summary by Managed Healthcare Executive
2 Articles
2 Articles
All
Left
Center
Right
Early Success of Adalimumab Biosimilars Featured at AMCP 2025
High adherence rates, comparable clinical effectiveness, and cost savings have marked the early adoption of adalimumab biosimilars in the US, particularly in formulary-driven transitions, as shown in 2 retrospective studies presented at the Academy of Managed Care Pharmacy annual meeting (AMCP 2025).
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage